We are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page, or call 1-877-436-3683. See the latest update on Actemra® (tocilizumab) supply here.

Our 2020 Diversity & Inclusion Report

At Genentech, embracing the increasingly diverse world around us is core to our business strategy. We believe in diversity of backgrounds and perspectives — including race/ethnicity, gender, LGBTQ+, veteran, and accessible communities — uniting us behind a common purpose and drawing on the strength of that diversity to drive better science and health outcomes.

We are determined to go faster. Be bolder. And we are doing just that across our three strategic pillars by:

Foster Belonging

We need the best and brightest minds, reflecting the increasingly diverse world around us, to pursue groundbreaking science that helps patients facing serious diseases.

Our 2025 Commitments

  • Double Black/African American and Hispanic/Latinx representation of directors and officers and extended leadership 1
  • Mirror Asian representation of directors and officers to that of Asian individual contributors and managers/supervisors
  • Address gender representation opportunity zones 2

Advance Inclusive Research & Health Equity

Addressing health inequity and inclusion in our research is increasingly central to our mission to improve patient health outcomes. We seek to deepen engagement with patient groups, healthcare providers, payers, government stakeholders and others to scale and advance health equity for all patients.

Our 2025 Commitments

  • Include population-specific assessments and inclusive research action plans on all molecule teams
  • Establish Genentech as a leader and partner of choice in advancing health equity

Transform Society

Advancing diversity and inclusion requires broad societal transformation; consequently, our D&I programs go beyond our company and the healthcare industry. We must work to identify and dismantle systemic barriers and replace them with pathways to equitable healthcare access, education and career opportunities and advancement.

Our 2025 Commitments

  • Commit $1 billion annually of our external spend to diverse suppliers 3
  • Require D&I commitments from all suppliers with requests for proposal of $500,000+ 4
  • Champion Kindergarten to Careers

Our 2025 Diversity & Inclusion Commitments speak to our people, our science and our societal efforts, and they serve as a transparent way to drive us forward.

Quita Highsmith, Chief Diversity Officer

1. Leadership pathways: Individual contributors include manufacturing, technical, laboratory and business support, as well as specialists/experts. Managers/supervisors are managers of people. Extended leadership is a subset of individual contributors and managers/supervisors, specifically those levels that are most likely to lead to director positions. Directors are managers of managers. Officers are managers of organizations.

2. We commit to taking a data-driven approach to uncover insights and ensure representation.

3. Diverse suppliers for Pharma defined as US-based businesses that are more than 51% owned by African American, Hispanic American, Asian American, women, veteran or LGBTQ+.

4. Dollar amount may decrease over time to bring more companies into the program.